Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

Abstract

BACKGROUND An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HCV genotype 1 infection. The addition of another potent agent, the NS5A inhibitor ABT-267, may… (More)
DOI: 10.1056/NEJMoa1306227

4 Figures and Tables

Topics

  • Blog articles referencing this paper

  • Presentations referencing similar topics